ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1688

Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study

Cal Robinson1, Francis Lao2, Rahul Chanchlani1, Anastasia Gayowsky3, Sandeep Brar4, Elizabeth Darling5, Catherine Demers5, Tapas Mondal1, Rulan Parekh6, Hsien Seow5 and Michelle Batthish1, 1McMaster Children's Hospital, Hamilton, ON, Canada, 2Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, 3ICES McMaster, Hamilton, ON, Canada, 4University of California, San Fransisco, 5McMaster University, Hamilton, ON, Canada, 6University of Toronto, Toronto, Canada

Meeting: ACR Convergence 2020

Keywords: Anxiety, Cognitive dysfunction, Disability, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome data among KD survivors. Our objectives were to determine the incidence and risk of hearing loss, anxiety, developmental disorders, intellectual disabilities and attention-deficit/hyperactivity disorder (ADHD) among KD survivors vs. non-exposed children.

Methods: We included all Ontario children (≤18yr) surviving hospitalization with a KD diagnosis between 1995-2018, through validated algorithms using population-based health administrative databases. We excluded children with a prior KD diagnosis, non-residents, and those with incomplete records. KD cases were matched with 100 non-exposed children by age, sex and index admission year. Follow-up continued until death or March 2019. We calculated the prevalence, incidence (per 1000 person-years (py)) and unadjusted hazard ratios (HR) for each outcome between 0-1yr, 1-5yr, 5-10yr and >10yr.

Results: Among 4,597 KD survivors and 459,700 non-exposed children (median 11.1yr follow-up), KD survivors had more hearing loss: 364 cases (7.9%) vs. 31,442 (6.8%); anxiety disorders: 1,213 (26.4%) vs. 99,965 (21.8%); developmental disorders: 398 (8.7%) vs. 28,211 (6.1%); intellectual disabilities: 52 (1.1%) vs. 2,931 (0.6%); and ADHD: 21 (0.5%) vs. 1,214 (0.3%). Compared to non-exposed children, KD survivors were at increased risk of hearing loss between 0-1yr (HR 1.25 [95%CI 1.00-1.54]); anxiety disorders between 0-1yr (HR 1.75 [1.46-2.10]), 1-5yr (HR 1.12 [1.00-1.27]) and 5-10yr (HR 1.12 [1.00-1.25]); developmental disorders between 0-1yr (HR 1.66 [1.42-1.93]) and 1-5yr (HR 1.24 [1.06-1.46]); intellectual disabilities between 1-5yr (HR 1.64 [1.07-2.53]) and >10yr (HR 2.55 [1.47-4.43]); and ADHD >10yr after index hospitalization (HR 1.97 [1.11-3.48]).

Conclusion: KD survivors are at increased risks of adverse neurodevelopmental outcomes, which may impair their academic and social functioning. This justifies enhanced developmental and audiological surveillance of KD survivors.

Table 1. Incidence and risk of hearing loss, anxiety and neurodevelopmental disorders, comparing KD vs. non-exposed children at 0-1yr, 1-5yr, 5-10yr and >10yr follow-up

Figure 1. Anxiety disorder-free survival among KD survivors vs. non-exposed children


Disclosure: C. Robinson, None; F. Lao, None; R. Chanchlani, None; A. Gayowsky, None; S. Brar, None; E. Darling, None; C. Demers, None; T. Mondal, None; R. Parekh, None; H. Seow, None; M. Batthish, Abbvie, 2.

To cite this abstract in AMA style:

Robinson C, Lao F, Chanchlani R, Gayowsky A, Brar S, Darling E, Demers C, Mondal T, Parekh R, Seow H, Batthish M. Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/long-term-hearing-loss-anxiety-and-neurodevelopmental-outcomes-following-kawasaki-disease-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-hearing-loss-anxiety-and-neurodevelopmental-outcomes-following-kawasaki-disease-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology